It only takes one counter-example to disprove an absolute statement like “fondaparinux (Arixtra) never causes HIT”. We now have a counter-example in the form of a letter to the editor of NEJM which documents a case of HIT due to fondaparinux. So much for its emergence as a treatment for HIT!
H/T to the Mayo Hospital Medidine update!
2 comments:
A single letter to the NEJM doesn't warrant a change in the standard of care. We need more data, not more opining.
Donald Sweet, MD, FACP
Of course it doesn't. But Arixtra never was the standard of care for HIT.
Post a Comment